Mesenchymal cell interaction with ovarian cancer cells induces a background dependent pro-metastatic transcriptomic profile

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Lis, Raphael ^a   Touboul, Cyril ^a   Halabi, Najeeb M ^a   Madduri, Abishek S ^b   Querleu, Denis ^c   Mezey, Jason ^b   Malek, Joel A ^a   Suhre, Karsten ^b   Rafii, Arash ^a,b,d  

^a WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Genomic modification; Mesenchymal stem cell; Metastasis; Ovarian cancer; Transcriptome

Indexed keywords

TRANSCRIPTOME;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CELL ADHESION; CELL INTERACTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHEMORESISTANCE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENOME; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MESENCHYME CELL; METASTASIS; OVARY CANCER; TRANSCRIPTOMICS; TUMOR INVASION;

CELL ADHESION; CELL COMMUNICATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MESENCHYMAL STROMAL CELLS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PRINCIPAL COMPONENT ANALYSIS; TRANSCRIPTOME;

EID: 84897578125     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-59     Document Type: Article

References (41)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004, 351:2519-2529. 10.1056/NEJMra041842, 15590954.
2. Ceelen WP, Bracke ME. Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. Lancet Oncol 2009, 10:72-79. 10.1016/S1470-2045(08)70335-8, 19111247.
3. Zhang S, Wang J, Bilen M, Lin S-H, Stupp S, Satcher R. Modulation of prostate cancer cell gene expression by cell-to-cell contact with bone marrow stromal cells or osteoblasts. Clin Exp Metastasis 2009, 26:993-1004. 10.1007/s10585-009-9289-0, 19787436.
4. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, Korkaya H, Heath A, Dutcher J, Kleer CG, Jung Y, Dontu G, Taichman R, Wicha MS. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011, 71:614-624. 10.1158/0008-5472.CAN-10-0538, 3100554, 21224357.
5. Lis R, Touboul C, Mirshahi P, Ali F, Mathew S, Nolan DJ, Maleki M, Abdalla SA, Raynaud CM, Querleu D, Al-Azwani E, Malek J, Mirshahi M, Rafii A. Tumor associated mesenchymal stem cells protects ovarian cancer cells from hyperthermia through CXCL12. Int J Cancer 2011, 128:715-725. 10.1002/ijc.25619, 20725999.
6. Coffelt SB, Marini FC, Watson K, Zwezdaryk KJ, Dembinski JL, LaMarca HL, Tomchuck SL, zu Bentrup KH, Danka ES, Henkle SL, Scandurro AB. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci 2009, 106:3806-3811. 10.1073/pnas.0900244106, 2656161, 19234121.
7. Pasquet M, Golzio M, Mery E, Rafii A, Benabbou N, Mirshahi P, Hennebelle I, Bourin P, Allal B, Teissie J, Mirshahi M, Couderc B. Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis. Int J Cancer 2010, 126:2090-2101.
8. Martinet L, Poupot R, Mirshahi P, Rafii A, FourniÈ J-J, Mirshahi M, Poupot M. Hospicells derived from ovarian cancer stroma inhibit T-cell immune responses. Int J Cancer 2010, 126:2143-2152.
9. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE 2009, 4:e4992. 10.1371/journal.pone.0004992, 2661372, 19352430.
10. Touboul C, Lis R, Al Farsi H, Raynaud CM, Warfa M, Althawadi H, Mery E, Mirshahi M, Rafii A. Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model. J Transl Med 2013, 11:28. 10.1186/1479-5876-11-28, 3582577, 23369187.
11. Cancer Genome Atlas Research N Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. 10.1038/nature10166, 3163504, 21720365, Cancer Genome Atlas Research N.
12. Malek JA, Martinez A, Mery E, Ferron G, Huang R, Raynaud C, Jouve E, Thiery JP, Querleu D, Rafii A. Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis. J Transl Med 2012, 10:121. 10.1186/1479-5876-10-121, 3477065, 22687175.
13. Malek JA, Mery E, Mahmoud YA, Al-Azwani EK, Roger L, Huang R, Jouve E, Lis R, Thiery JP, Querleu D, Rafii A. Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis. PLoS One 2011, 6:e28561. 10.1371/journal.pone.0028561, 3237432, 22194851.
14. Lis R, Touboul C, Raynaud CM, Malek JA, Suhre K, Mirshahi M, Rafii A. Mesenchymal cell interaction with ovarian cancer cells triggers pro-metastatic properties. PLoS One 2012, 7:e38340. 10.1371/journal.pone.0038340, 3364218, 22666502.
15. Jeon ES, Moon HJ, Lee MJ, Song HY, Kim YM, Cho M, Suh D-S, Yoon M-S, Chang CL, Jung JS, Kim JH. Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells. Stem Cells 2008, 26:789-797. 10.1634/stemcells.2007-0742, 18065393.
16. Ahmed N, Riley C, Rice G, Quinn M. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis 2005, 22:391-402. 10.1007/s10585-005-1262-y, 16283482.
17. Zand L, Feng Q, Roskelley C, Leung P, Auersperg N. Differential effects of cellular fibronectin and plasma fibronectin on ovarian cancer cell adhesion, migration, and invasion. In Vitro Cell Dev Biol - Animal 2003, 39:178-182.
18. Sundfeldt K, Piontkewitz Y, Ivarsson K, Nilsson O, Hellberg P, Brannstrom M, Janson PO, Enerback S, Hedin L. E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer 1997, 74:275-280. 10.1002/(SICI)1097-0215(19970620)74:3<275::AID-IJC7>3.0.CO;2-W, 9221804.
19. Strauss R, Li ZY, Liu Y, Beyer I, Persson J, Sova P, Moller T, Pesonen S, Hemminki A, Hamerlik P, Drescher C, Urban N, Bartek J, Lieber A. Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS ONE 2011, 6:e16186. 10.1371/journal.pone.0016186, 3021543, 21264259.
20. Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 2008, 118:1367-1379. 10.1172/JCI33775, 2267016, 18340378.
21. Barbieri F, Bajetto A, Florio T. Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target. J Oncol 2010, 2010:426956. 2798669, 20049170.
22. Qian B-Z, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225. 10.1038/nature10138, 3208506, 21654748.
23. Chang W, Ma L, Lin L, Gu L, Liu X, Cai H, Yu Y, Tan X, Zhai Y, Xu X, Zhang M, Wu L, Zhang H, Hou J, Wang H, Cao G. Identification of novel hub genes associated with liver metastasis of gastric cancer. Int J Cancer 2009, 125:2844-2853. 10.1002/ijc.24699, 19569046.
24. Couderc B, Pradines A, Rafii A, Golzio M, Deviers A, Allal C, Berg D, Penary M, Teissie J, Favre G. In vivo restoration of RhoB expression leads to ovarian tumor regression. Cancer Gene Ther 2008, 15:456-464. 10.1038/cgt.2008.12, 18340357.
25. Ramachandran S, Shida D, Nagahashi M, Fang X, Milstien S, Takabe K, Spiegel S. Lysophosphatidic acid stimulates gastric cancer cell proliferation via ERK1-dependent upregulation of sphingosine kinase 1 transcription. FEBS Lett 2010, 584:4077-4082. 10.1016/j.febslet.2010.08.035, 2947956, 20804754.
26. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, Lasorella A, Aldape K, Califano A, Iavarone A. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010, 463:318-325. 10.1038/nature08712, 20032975.
27. Sher I, Adham SA, Petrik J, Coomber BL. Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. Int J Cancer 2009, 124:553-561. 10.1002/ijc.23963, 19004006.
28. Said NA, Elmarakby AA, Imig JD, Fulton DJ, Motamed K. SPARC ameliorates ovarian cancer-associated inflammation. Neoplasia 2008, 10:1092-1104. 2546586, 18813349.
29. Tai IT, Tang MJ. SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat 2008, 11:231-246. 10.1016/j.drup.2008.08.005, 18849185.
30. Miyoshi K, Sato N, Ohuchida K, Mizumoto K, Tanaka M. SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients. Anticancer Res 2010, 30:867-871.
31. Fenouille N, Puissant A, Tichet M, Zimniak G, Abbe P, Mallavialle A, Rocchi S, Ortonne JP, Deckert M, Ballotti R, Tartare-Deckert S. SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival. Oncogene 2011, 30(49):4887-4900. 10.1038/onc.2011.198, 21685937.
32. Schwarz RE, Awasthi N, Konduri S, Caldwell L, Cafasso D, Schwarz MA. Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation. Cancer Biol Ther 2010, 9:632-639. 10.4161/cbt.9.8.11265, 20212356.
33. Roman J, Ritzenthaler JD, Roser-Page S, Sun X, Han S. {alpha}5{beta}1-integrin expression is essential for tumor progression in experimental lung cancer. Am J Respir Cell Mol Biol 2010, 43:684-691. 10.1165/rcmb.2009-0375OC, 2993088, 20081050.
34. De Smaele E, Zazzeroni F, Papa S, Nguyen DU, Jin R, Jones J, Cong R, Franzoso G. Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. Nature 2001, 414:308-313. 10.1038/35104560, 11713530.
35. Gupta M, Gupta SK, Balliet AG, Hollander MC, Fornace AJ, Hoffman B, Liebermann DA. Hematopoietic cells from Gadd45a- and Gadd45b-deficient mice are sensitized to genotoxic-stress-induced apoptosis. Oncogene 2005, 24:7170-7179. 10.1038/sj.onc.1208847, 16170381.
36. Dong L, Wen J, Pier E, Zhang X, Zhang B, Dong F, Ziegler N, Mysz M, Armenta R, Cui R. Melanocyte-stimulating hormone directly enhances UV-induced DNA repair in keratinocytes by a xeroderma pigmentosum group a-dependent mechanism. Cancer Res 2010, 70:3547-3556. 10.1158/0008-5472.CAN-09-4596, 2862104, 20388774.
37. De Toni-Costes F, Despeaux M, Bertrand J, Bourogaa E, Ysebaert L, Payrastre B, Racaud-Sultan C. A New alpha5beta1 integrin-dependent survival pathway through GSK3Œ ≤ activation in leukemic cells. PLoS ONE 2010, 5:e9807. 10.1371/journal.pone.0009807, 2843713, 20352103.
38. Xing H, Weng D, Chen G, Tao W, Zhu T, Yang X, Meng L, Wang S, Lu Y, Ma D. Activation of fibronectin/PI-3 K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett 2008, 261:108-119. 10.1016/j.canlet.2007.11.022, 18171600.
39. Xing H, Cao Y, Weng D, Tao W, Song X, Wang W, Meng L, Xu G, Zhou J, Wang S, Ma D. Fibronectin-mediated activation of Akt2 protects human ovarian and breast cancer cells from docetaxel-induced apoptosis via inhibition of the p38 pathway. Apoptosis 2008, 13:213-223. 10.1007/s10495-007-0158-5, 18158623.
40. Choi J-H, Park JT, Davidson B, Morin PJ, Shih I-M, Wang T-L. Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res 2008, 68:5716-5723. 10.1158/0008-5472.CAN-08-0001, 2562671, 18632624.
41. McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, Cabrera L, Keller E, McCauley L, Cho KR, Buckanovich RJ. Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest 2011, 121:3206-3219. 10.1172/JCI45273, 3148732, 21737876.